Those with hemophilia A (HA) who switched from standard half-life factor VIII (FVIII)—a clotting protein these folks lack—to rFVIIIFc, an extended half-life recombinant version that remains in the bloodstream longer, experienced fewer bleeds, required less frequent injections and used less factor overall, according to a study published in Hematology .

The study findings highlight the therapy’s effectiveness in reducing both disease and treatment burden for those with HA.

HA is a genetic bleeding disorder caused by a deficiency of FVIII, a protein essential for normal blood clotting. Folks with severe HA typically require prophylactic treatment with clotting factor concentrates (CFCs) to prevent bleeding and preserve joint health, as repeated bleeding into joints and muscles can cause e

See Full Page